Cannabinoide, darunter THC und CBD, reduzieren die Bildung reaktiver Sauerstoffspezies (ROS), einem zentralen pathologischen Treiber bei neurodegenerativen Erkrankungen und einer verstärkten Konsequenz, die bei neuropsychiatrischen Erkrankungen wie MDD, AD, SZ, OCD, PTBS und Autismus beobachtet wird.
https://www.mdpi.com/1424-8247/18/12/1817
6 Kommentare
###Abstract
Background and Objectives: Neuropsychiatric disorders pose a major global health challenge, marked by high prevalence, limited diagnostic precision, and suboptimal therapeutic outcomes. Current diagnoses remain primarily clinical, lacking objective biomarkers, while many patients experience poor remission rates and frequent relapse. The endocannabinoid system (ECS), a central regulator of synaptic plasticity, neuroinflammation, and stress responses, is increasingly implicated in depression, anxiety, schizophrenia, and neurodegenerative diseases. In parallel, extracellular vesicles (EVs) have emerged as critical mediators of intercellular communication and promising biomarker sources, as they reflect the physiological or pathological status of their cells of origin. This review examines the hypothesis that interactions between ECS signaling and EV-mediated communication form a convergent pathway shaping vulnerability and resilience in neuropsychiatric disorders, with potential implications for biomarker identification and therapeutic innovation. Methods: This hypothesis-driven review was developed using a narrative approach, focusing on the interface between cannabinoids and EVs in neuropsychiatric conditions. Relevant publications were identified through PubMed, Scopus, and Web of Science searches up to September 2025. Results: Emerging evidence indicates a bidirectional relationship between ECS activity and EV biology: endocannabinoids can be loaded into EVs to facilitate intercellular signaling, while phytocannabinoids such as THC and CBD can alter EV release and cargo composition. Conclusions: We propose a hypothesis-driven framework in which the possible interplay between cannabinoids and EVs may stimulate new research and support the development of biomarker-guided, personalized therapeutic strategies for neuropsychiatric disorders.
I’ll make it easy, if you’re a person who has mental issues already such as anxiety, the common one that people think is OK to have. Don’t smoke weed. Weed is not helping out people with mental illnesses. It’s bad for you.
But what weed can do is alert you if you’re having a bad time on it that you legitimately have mental illness issues and should check up on it.
Edit-
This paper suggests that cannabinoids affect brain signaling pathways involved in mental illness, and that people with existing vulnerability may respond poorly. A negative reaction could reflect underlying susceptibility.
the paper avoids beings as definite as I am, but basically that’s what it’s saying.
Hmm. So instead of studying why the endocannabanadiome exists in perpetuity with cannabis and its specific biochem ; bypass that entirety and make it from scratch on a personalized level in the same system. What a genius work around (/s)
Sounds like it’s gonna be a lot easier to study.. with cannabis than without it. But what do I know – it’s just the bold face interpretations of only cbd and thc with out any antecedents about flavor/high/effect/intake/consumption/freshness/quality and there surely won’t be fantastic answers to their questions there.
Well hopefully one day soon we’ll stop pretending whats clearly going on an interacting with *75%* of world health problems.
But New Zealand wont let me drive for 12 hours after I’ve used my medication to make my brain work better, make it make sense
Typical anti marijuana bs with dubious research methods and funding aimed at demonizing a very safe and fun substance. Would not be surprised if this “study” was funded by the alcohol or tobacco industry. Think more critically.
„Autism“ rather than ASD makes me think study started long ago??